D.P. O'Sullivan, BE, Our Lady's Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland;
I. Steinkoenig, BA, Cleveland Clinic, Cleveland, Ohio, USA.
J Rheumatol Suppl. 2021 Jun;97:64. doi: 10.3899/jrheum.201680.
Eleven patient research partners (PRPs) attended the virtual Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 Annual Meeting. PRPs fully participated in the panel discussion at the 2020 GRAPPA Annual Meeting on the topic of the coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2). The members of the PRP group have been involved in many GRAPPA projects over the last year, including work on the GRAPPA-Outcome Measures in Rheumatology (OMERACT) Core Set, GRAPPA's 2020 Treatment Guidelines update project, and GRAPPA's Collaborative Research Network project.
11 位患者研究伙伴（PRP）参加了虚拟的银屑病和银屑病关节炎研究与评估团体（GRAPPA）2020 年年会。PRP 充分参与了 2020 年 GRAPPA 年会上关于 2019 年冠状病毒病（COVID-19；由 SARS-CoV-2 引起）主题的小组讨论。该 PRP 小组的成员在过去一年中参与了许多 GRAPPA 项目，包括 GRAPPA-OMERACT（关节炎疗效评估的 OMERACT）核心集、GRAPPA 2020 年治疗指南更新项目和 GRAPPA 合作研究网络项目。
